Highly selective apoptotic cell death induced by Halo-Salane titanium complexes

ChemMedChem

Volumn 4, Issue 5, 2009, Pages 738-741

  Immel, Timo A ^a   Debiak, Malgorzata ^a   Groth, Ulrich ^a   Bürkle, Alexander ^a   Huhn, Thomas ^a  

^a UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

Antitumor agents; Apoptosis; Cytotoxicity; Structure activity relationships; Titanium complexes

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; HALOGEN SALANE TITANIUM COMPLEX; UNCLASSIFIED DRUG; ORGANOMETALLIC COMPOUND; TITANIUM;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN HEPG2; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG CYTOTOXICITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SELECTIVITY; DRUG SYNTHESIS; FEMALE; HELA CELL; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; ROOM TEMPERATURE; CHEMISTRY; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; HELA CELLS; HUMANS; ORGANOMETALLIC COMPOUNDS; TITANIUM;

EID: 67651114107     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200900038     Document Type: Article

References (31)

1. B. Rosenberg, L. van Camp, T. Krigas, Nature 1965, 205, 698-699.
2. B. Rosenberg, L. van Camp, J. E. Trosko, V. H. Mansour, Nature 1969, 222, 385-386.
3. F. Caruso, M. Rossi, J. Tanski, R. Sartori, R. Sariego, S. Moya, S. Diez, E. Navarrete, A. Cingolani, F. Marchetti, C. Pettinari, J. Med. Chem. 2000, 43, 3665-3670.
4. I. Ott, R. Gust, Arch. Pharm. Chem. Life Sci. 2007, 340, 117-126.
5. P. Köpf-Maier, F. Preiss, T. Marx, T. Klapötke, H. Köpf, Anticancer Res. 1986, 6, 33-37.
6. B. Desoize, Anticancer Res. 2004, 24, 1529-1544.
7. K. Strohfeldt, M. Tacke, Chem. Soc. Rev. 2008, 37, 1174-1187.
8. H. Köpf, P. Köpf-Maier, Angew. Chem. 1979, 91, 509;
9. Angew. Chem. Int. Ed. Engl. 1979, 18, 477-478.
10. F. Caruso, M. Rossi, Mini-Rev. Med. Chem. 2004, 4, 49-60.
11. M. M. Harding, G. Mokdsi, Curr. Med. Chem. 2000, 7, 1289-1303.
12. G. Lümmen, H. Sperling, H. Luboldt, T. Otto, H. Rübben, Cancer Chemother. Pharmacol. 1998, 42, 415-417.
13. T. Schilling, K. B. Keppler, M. E. Heim, G. Niebch, H. Dietzfelbinger, J. Rastetter, A. R. Hanauske, Invest. New Drugs 1995, 13, 327-332.
14. J. H. Toney, T. J. Marks, J. Am. Chem. Soc. 1985, 107, 947-953.
15. P. Köpf-Maier, Eur. J. Clin. Pharmacol. 1994, 47, 1-16.
16. C. V. Christodoulou, A. G. Eliopoulos, L. S. Young, L. Hodgkins, D. R. Ferry, D. J. Kerr, Br. J. Cancer 1998, 77, 2088-2097.
17. E. Melendez, Crit. Rev. Oncol. Hematol. 2002, 42, 309-315.
18. M. Guo, Z. Guo, P. J. Sadler, J. Biol. Inorg. Chem. 2001, 6, 698-707.
19. G. Mokdsi, M. M. Harding, J. Inorg. Biochem. 2001, 83, 205-209.
20. A. D. Tinoco, C. D. Incarvito, A. M. Valentine, J. Am. Chem. Soc. 2007, 129, 3444-3454.
21. A. D. Tinoco, E. V. Eames, A. M. Valentine, J. Am. Chem. Soc. 2008, 130, 2262-2270.
22. M. Shavit, D. Peri, C. M. Manna, J. S. Alexander, E. Y. Tshuva, J. Am. Chem. Soc. 2007, 129, 12098-12099.
23. E. Y. Tshuva, N. Gendeziuk, M. Kol, Tetrahedron Lett. 2001, 42, 6405-6407.
24. S. Gendler, S. Segal, I. Goldberg, Z. Goldschmidt, M. Kol, Inorg. Chem. 2006, 45, 4783-4790.
25. J. Balsells, P. J. Carroll, P. Walsh, J. Inorg. Chem. 2001, 40, 5568-5574.
26. R. Hamid, Y. Rotshteyn, L. Rabadi, R. Parikh, P. Bullock, Toxicol. in Vitro 2004, 18, 703-710.
27. R. de Fries, M. Mitsuhashi, J. Clin. Lab. Anal. 1995, 9, 89-95.
28. J. Claffey, M. Hogan, H. Müller-Bunz, C. Pampillon, M. Tacke, ChemMed-Chem 2008, 3, 729-731.
29. S. Fulda, K. M. Debatin, Curr. Cancer Drug Targets 2004, 4, 569-576.
30. A. Gansäuer, I. Winkler, D. Worgull, T. Lauterbach, D. Franke, A. Selig, L. Wagner, A. Prokop, Chem. Eur. J. 2008, 14, 4160-4163.
31. K. O'Connor, C. Gill, M. Tacke, F. J. Rehmann, K. Strohfeldt, N. Sweeney, J. M. Fitzpatrik, R. W. Watson, Apoptosis 2006, 11, 1205-1214.